Kevin Richard C, Cairns Elizabeth A, Boyd Rochelle, Arnold Jonathon C, Bowen Michael T, McGregor Iain S, Banister Samuel D
The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Camperdown, NSW, Australia.
School of Pharmacy, The University of Sydney, Camperdown, NSW, Australia.
Front Psychiatry. 2022 Dec 15;13:1048836. doi: 10.3389/fpsyt.2022.1048836. eCollection 2022.
Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances that have been associated with multiple instances and types of toxicity. Some SCRAs appear to carry a greater toxicological burden than others, or compared to the prototypical cannabis-derived agonist Δ-tetrahydrocannabinol (Δ-THC), despite a common primary mechanism of action cannabinoid 1 (CB1) receptors. "Off-target" (i.e., non-CB1 receptor) effects could underpin this differential toxicity, although there are limited data around the activity of SCRAs at such targets.
A selection of 7 SCRAs (AMB-FUBINACA, XLR11, PB-22, AKB-48, AB-CHMINICA, CUMYL-PINACA, and 4F-MDMB-BUTINACA), representing several distinct chemotypes and toxicological profiles, underwent a 30 μM single-point screen against 241 G protein-coupled receptor (GPCR) targets in antagonist and agonist mode using a cellular β-arrestin recruitment assay. Strong screening "hits" at specific GPCRs were followed up in detail using concentration-response assays with AMB-FUBINACA, a SCRA with a particularly notable history of toxicological liability.
The single-point screen yielded few hits in agonist mode for any compound aside from CB1 and CB2 receptors, but many hits in antagonist mode, including a range of chemokine receptors, the oxytocin receptor, and histamine receptors. Concentration-response experiments showed that AMB-FUBINACA inhibited most off-targets only at the highest 30 μM concentration, with inhibition of only a small subset of targets, including H histamine and α adrenergic receptors, at lower concentrations (≥1 μM). AMB-FUBINACA also produced concentration-dependent CB1 receptor signaling disruption at concentrations higher than 1 μM, but did not produce overt cytotoxicity beyond CP55,940 or Δ-THC in CB1 expressing cells.
These results suggest that while some "off-targets" could possibly contribute to the SCRA toxidrome, particularly at high concentrations, CB1-mediated cellular dysfunction provides support for hypotheses concerning on-target, rather than off-target, toxicity. Further investigation of non-GPCR off-targets is warranted.
合成大麻素受体激动剂(SCRAs)是一类多样的新型精神活性物质,与多种毒性事件和类型相关。尽管作用的主要机制相同——作用于大麻素1(CB1)受体,但一些SCRAs似乎比其他物质,或与典型的源自大麻的激动剂Δ-四氢大麻酚(Δ-THC)相比,具有更大的毒理学负担。“脱靶”(即非CB1受体)效应可能是这种毒性差异的基础,尽管关于SCRAs在此类靶点活性的数据有限。
选择了7种SCRAs(AMB-FUBINACA、XLR11、PB-22、AKB-48、AB-CHMINICA、CUMYL-PINACA和4F-MDMB-BUTINACA),它们代表了几种不同的化学类型和毒理学特征,使用细胞β-抑制蛋白募集试验,以拮抗剂和激动剂模式针对241种G蛋白偶联受体(GPCR)靶点进行了30μM的单点筛选。对于在特定GPCR上的强筛选“命中”,使用AMB-FUBINACA进行浓度响应试验进行详细跟进,AMB-FUBINACA是一种具有特别显著毒理学责任历史的SCRAs。
除了CB1和CB2受体外,单点筛选在激动剂模式下对任何化合物产生的“命中”都很少,但在拮抗剂模式下有许多“命中”,包括一系列趋化因子受体、催产素受体和组胺受体。浓度响应实验表明,AMB-FUBINACA仅在最高30μM浓度下抑制大多数脱靶,在较低浓度(≥1μM)下仅抑制一小部分靶点,包括组胺H和α肾上腺素能受体。AMB-FUBINACA在高于1μM的浓度下也会产生浓度依赖性的CB1受体信号破坏,但在表达CB1的细胞中不会产生超过CP55,940或Δ-THC的明显细胞毒性。
这些结果表明,虽然一些“脱靶”可能对SCRAs中毒综合征有贡献,特别是在高浓度时,但CB1介导的细胞功能障碍为关于靶点毒性而非脱靶毒性的假说提供了支持。有必要对非GPCR脱靶进行进一步研究。